arrow
S

Sandro Pasquali

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:41
被引数:6,458

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Paediatric therapeutic development workshop on desmoplastic small round cell tumours

儿科治疗药物开发研讨会关于纤维性小圆细胞肿瘤

2026-10-140
OAAI
Pain in Epithelioid Hemangioendothelioma: Development of Disease-Specific Pain Assessment Criteria (PAC-E)

上皮样血管内皮瘤的疼痛:疾病特异性疼痛评估标准(PAC-E)的开发

2026-10-060
OA
Translational aspects of Desmoplastic Small Round Cell Tumor (DSRCT): An expert consensus paper from the OCTOPUS group

弥漫性小圆细胞肿瘤(DSRCT)的转化研究方面:OCTOPUS小组专家共识论文

2026-06-020
PRE
Neoadjuvant chemotherapy for soft-tissue sarcoma of the extremities: A post-hoc Sarculator-based risk analysis of the EORTC 62961-ESHO 95 randomized trial

四肢软组织肉瘤的新辅助化疗:基于EORTC 62961-ESHO 95随机试验的Sarculator后效风险分析

Cancer
IF5.1
2026-05-010
OAAI
Refining the Contemporary Management of Primary Retroperitoneal Soft Tissue Sarcoma: Outcome Improvement Over Time at a Single Institution

优化原发性腹膜后软组织肉瘤的现代管理:单中心随时间推移的结局改善

2025-12-130
PRE
Extended molecular profiling in mesenchymal tumors: a consensus paper from the Italian Sarcoma Group

间质肿瘤的扩展分子分析:意大利肉瘤组共识论文

2025-09-230
PREAI
Establishment of patient-derived 3D in vitro models of sarcomas: literature review and guidelines on behalf of the FORTRESS working group

建立来源于患者的肉瘤3D体外模型:文献综述和FORTRESS工作组指南

2025-07-010
PRE
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial

重新定义接受新辅助化疗的高风险软组织肉瘤的放射学反应:ISG-STS 1001随机临床试验的最终结果

2025-03-010
OAAI
Proximal and Classic Epithelioid Sarcomas are Distinct Molecular Entities Defined by MYC/GATA3 and SOX17/Endothelial Markers, Respectively
2025-01-010
OAAI
Radiomic features of primary retroperitoneal sarcomas: a prognostic study
2024-12-010
PRE
Preoperative nutritional support to tackle morbidity in multivisceral resection for retroperitoneal sarcoma. Early outcomes from a novel nutritional prehabilitation program in a prospective cohort
EJSO
IF2.9
2024-12-012
PRE